Zometa

DRUG9 trials

Conditions

Bone MetastasesBreast CancerBreast NeoplasmsHigh NTX LevelMesotheliomaMultiple MyelomaNon Small Cell Lung CancerProstate Cancer

Phase 2

Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide

CompletedNCT00083382

University of ArkansasMultiple Myeloma

Start: 1998-12-31End: 2014-05-31Updated: 2015-06-24

Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer

CompletedNCT00242203

Washington University School of MedicineBreast Neoplasms

Start: 2002-10-31End: 2011-05-31Updated: 2013-08-13

Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy

CompletedNCT00582556

University of Wisconsin, MadisonProstate Cancer

Start: 2003-04-30End: 2013-03-31Updated: 2019-11-26

Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy

CompletedNCT00582556

University of Wisconsin, MadisonProstate Cancer

Start: 2003-04-30End: 2013-03-31Updated: 2019-11-26

Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)

CompletedNCT01204203

University of Alabama at BirminghamMesothelioma

Start: 2009-06-30End: 2016-04-30Updated: 2017-05-24

Phase 3

ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases

TerminatedNCT00294437

Central European Cooperative Oncology GroupProstate Cancer

Start: 2003-12-31End: 2007-11-30Updated: 2012-05-01

Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL)

CompletedNCT00712985

Milton S. Hershey Medical CenterBreast Cancer

Start: 2005-09-30End: 2011-03-31Updated: 2014-04-24

Phase 4

Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis

CompletedNCT00035997

Novartis PharmaceuticalsProstate Cancer

Start: 2002-04-30End: 2004-01-31Updated: 2009-11-23

Stage I Multiple Myeloma Treatment

CompletedNCT00733538

Centre Hospitalier Universitaire de NiceMultiple Myeloma

Start: 2004-12-31End: 2012-11-30Updated: 2024-04-12

Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis

CompletedNCT00762346

Sun Yat-sen UniversityBone Metastases, High NTX Level, Non Small Cell Lung Cancer

Start: 2008-09-30End: 2013-03-31Updated: 2013-12-10

Related Papers

Long-term outcome of (neo)adjuvant zoledronic acid therapy in locally advanced breast cancer.

2021-02-167 citations

A Randomised Controlled Trial of Intravenous Zoledronic Acid in Malignant Pleural Disease: A Proof of Principle Pilot Study

PLoS ONE2015-03-177 citations

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.

2010-03-31204 citations

Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.

2008-07-3178 citations